KPRX — KIORA PHARMACEUTICALS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1372514 ·
Last close
$0.93
Market Cap
$4.11M
52W High
$2.91
52W Low
$0.93
ADV30
54,330
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -2,124,357 | -2,079,010 | 23,776,090 | 7,076,533 | 6,919,401 |
| Mar 2026 | 0 | — | -2,502,768 | -2,417,984 | 21,227,089 | 10,955,359 | 7,292,528 |
| Dec 2025 | 0 | — | -2,630,193 | -6,516,521 | 24,253,300 | 8,696,570 | 8,126,764 |
| Sep 2025 | 0 | — | -2,515,470 | 26,806 | 29,863,454 | 5,508,899 | 7,452,712 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-8,506,809
Investing CF
$9,601,536
Financing CF
$4,918,285
CapEx
$-107,068
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-1.45
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-158,714,270
Inventory
—
Receivables
$2,906,464
ST Investments
$9,761,994
EBIT TTM
$-12,410,884
Pretax Income TTM
$-12,279,808
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -9,459,247 | -10,835,154 | 24,253,300 | 8,126,764 | 16,126,536 | -9,961,176 |
| Dec 2024 | 16,000,000 | 5,580,819 | 3,594,733 | 36,484,484 | 10,724,708 | 25,759,776 | 8,559,115 |
| Dec 2023 | 0 | -8,690,183 | -12,513,896 | 13,711,870 | 7,602,216 | 6,109,654 | -9,556,951 |
| Dec 2022 | 0 | -11,726,918 | -13,583,610 | 18,678,259 | 7,270,659 | 11,407,600 | -10,428,133 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-10,986,709
OpCashFlow TTM
—
Assets (Latest)
$23,776,090
Forward EPS
$-2.23
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RVPH | REVIVA PHARMACEUTICALS HOLDINGS, INC. | $4.02M | $0.31 | — |
| TCRT | Alaunos Therapeutics, Inc. | $4.22M | $1.66 | — |
| SILO | Silo Pharma, Inc. | $4.00M | $1.71 | — |
| XTLB | XTL BIOPHARMACEUTICALS LTD | $3.98M | $1.62 | — |
| IMNN | Imunon, Inc. | $3.97M | $0.61 | — |
News headlines (Yahoo Finance, 1h cache)
Kiora Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-12 12:00 · Yahoo
Kiora Pharmaceuticals In-Licenses Late-Stage, Oral Neuroprotective Calpain Inhibitor for Central Retinal Artery Occlusion (CRAO) with Planned Expansion into NAION; Asset Completed Phase 3 Clinical Tri
2026-10-29 11:00 · Yahoo
Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation
2026-08-19 11:00 · Yahoo
Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium
2026-07-02 11:00 · Yahoo
Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway
2026-04-14 11:00 · Yahoo
Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors
2026-04-07 11:00 · Yahoo
Kiora Pharmaceuticals Announces Management Team Changes
2026-04-02 20:30 · Yahoo
Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-08 11:00 · Yahoo
Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs
2026-09-08 11:00 · Yahoo
SS Innovations International (SSII) Appoints Sarah Romano as Chief Financial Officer
2026-07-15 18:25 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.